Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN3B | O60391 | 4/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.35 |
| ▸ | KDR | P35968 | 11/20 | 0.33 |
| ▸ | FLT1 | P17948 | 9/20 | 0.33 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284437 | 0.86 | SMN1; SMN2 (0.33) | GRIN3BGRIN1GRIN2CKDRFLT1 | |
| SCHEMBL2282096 | 0.80 | MEN1 (0.39) | KDRFLT1 | |
| SCHEMBL2284581 | 0.80 | NPC1 (0.41) | KDRFLT1 | |
| SCHEMBL2282329 | 0.75 | DYRK1A (0.33) | — | |
| SCHEMBL29518244 | 0.75 | AXL (0.39) | KDR | |
| SCHEMBL307500 | 0.75 | AXL (0.39) | KDR | |
| SCHEMBL2288707 | 0.73 | FLT1 (0.35) | GRIN3BGRIN1GRIN2CKDRFLT1 | |
| SCHEMBL13186320 | 0.73 | GRIN2D (0.41) | GRIN3BGRIN1GRIN2CMAP3K8GRIN2D | |
| SCHEMBL14966472 | 0.70 | PDGFRB (0.58) | KDR | |
| SCHEMBL31745113 | 0.70 | NCF1 (0.38) | MAP3K8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1989211-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | Array Biopharma, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008063202-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | GRIN3B 1208/4885GRIN1 800/4885GRIN2C 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.